Citations

Showing 10 of 108036 citations.

Familial predisposition and genetic risk factors for lymphoma
Cerhan, James R. , Slager, Susan L. , Cerhan, James R , Slager, Susan L

Mayo Clinic

Blood | September 25, 2015 | Volume: 126 | Issue: 20 | Pages: 2265-2273

10.1182/blood-2015-04-537498 | PMID 26405224 Get It

Abstract Our understanding of familial predisposition to lymphoma (collectively defined as non-Hodgkin lymphoma [NHL], Hodgkin lymphoma [HL], and chronic lymphocytic leukemia [CLL]) outside of rare hereditary syndromes has progressed rapidly during the last decade. First-degree relatives of NHL, HL, and CLL patients have an ∼1.7-fold, 3.1-fold, and 8.5-fold elevated risk of developing NHL, HL, and CLL, respectively. These familial risks are elevated for multiple lymphoma subtypes and do not appear to be confounded by nongenetic risk factors, suggesting at least some shared genetic etiology across the lymphoma subtypes. However, a family history of a specific subtype is most strongly associated with risk for that subtype, supporting subtype-specific genetic factors. Although candidate gene studies have had limited success in identifying susceptibility loci, genome-wide association studies (GWAS) have successfully identified 67 single nucleotide polymorphisms from 41 loci, predominately associated with specific subtypes. In general, these GWAS-discovered loci are common (minor allele frequency >5%), have small effect sizes (odds ratios, 0.60-2.0), and are of largely unknown function. The relatively low incidence of lymphoma, modest familial risk, and the lack of a screening test and associated intervention, all argue against active clinical surveillance for lymphoma in affected families at this time.
IL17 Functions through the Novel REG3β–JAK2–STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer
Loncle, Céline, Bonjoch, Laia , Folch‐Puy, Emma , López‐Millán, Belén , Lac, Sophie, Molejon, María Inés , Chuluyán, Eduardo , Cordelier, Pierre , Dubus, Pierre , Lomberk, Gwen , Closa, Daniel , Urrutia, Raúl , Iovanna, Juan , Lomberk, Gwen L

Mayo Clinic

Cancer Research | September 24, 2015 | Volume: 75 | Issue: 22 | Pages: 4852-4862

10.1158/0008-5472.can-15-0896 | PMID 26404002 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC) offers an optimal model for discovering “druggable” molecular pathways that participate in inflammation-associated cancer development. Chronic pancreatitis, a common prolonged inflammatory disease, behaves as a well-known premalignant condition that contributes to PDAC development. Although the mechanisms underlying the pancreatitis-to-cancer transition remain to be fully elucidated, emerging evidence supports the hypothesis that the actions of proinflammatory mediators on cells harboring Kras mutations promote neoplastic transformation. Recent elegant studies demonstrated that the IL17 pathway mediates this phenomenon and can be targeted with antibodies, but the downstream mechanisms by which IL17 functions during this transition are currently unclear. In this study, we demonstrate that IL17 induces the expression of REG3β, a well-known mediator of pancreatitis, during acinar-to-ductal metaplasia and in early pancreatic intraepithelial neoplasia (PanIN) lesions. Furthermore, we found that REG3β promotes cell growth and decreases sensitivity to cell death through activation of the gp130-JAK2-STAT3-dependent pathway. Genetic inactivation of REG3β in the context of oncogenic Kras-driven PDAC resulted in reduced PanIN formation, an effect that could be rescued by administration of exogenous REG3β. Taken together, our findings provide mechanistic insight into the pathways underlying inflammation-associated pancreatic cancer, revealing a dual and contextual pathophysiologic role for REG3β during pancreatitis and PDAC initiation. Cancer Res; 75(22); 4852–62. ©2015 AACR.
An unusual cause of ascites
Jha, Lokesh K. , Dingli, David , Dingli, David

Mayo Clinic

Blood | September 24, 2015 | Volume: 126 | Issue: 13 | Pages: 1629-1629

10.1182/blood-2015-06-649780 | PMID 26668859 Get It

Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk
Amankwah, Ernest K. , Lin, Hui‐Yi , Lawrenson, Kate , Chornokur, Ganna , Aben, Katja K.H. , Antonenkova, Natalia, Bruinsma, Fiona , Bean, Yukie T., Beckmann, Matthias W. , Bisogna, Maria, Bogdanova, Natalia , Brinton, Louise A. , Campbell, Ian , Chen, Zhihua , Chen, Y. Ann , Chang‐Claude, Jenny, Cunningham, Julie M. , Dansonka‐Mieszkowska, Agnieszka , Despierre, Evelyn, Dicks, Ed , Dörk, Thilo , Easton, Douglas F. , Eccles, Diana M., Edwards, Robert P., Ekici, Arif B. , Fasching, Peter A. , Gao, Yu‐Tang , Giles, Graham G. , Glasspool, Rosalind , Goodman, Marc T. , Harrington, Patricia, Harter, Philipp , Hasmad, Hanis Nazihah, Hein, Alexander , Heitz, Florian , Hildebrandt, Michelle A.T., Hillemanns, Peter , Høgdall, Claus , Høgdall, Estrid , Hosono, Satoyo , Iversen, Edwin S., Jakubowska, Anna , Jensen, Allan , Ji, Bu‐Tian , Kellar, Melissa, Kiemeney, Lambertus A. , Krakstad, Camilla , Kupryjańczyk, Jolanta , Lambrechts, Diether , Lambrechts, Sandrina, Le, Nhu D. , Lee, Alice W. , Lele, Shashi, Leminen, Arto, Lester, Jenny, Levine, Douglas A. , Liang, Dong , Lim, Boon Kiong , Lissowska, Jolanta , Lu, Karen, Lubiński, Jan , Lundvall, Lene, Massuger, Leon F.A.G. , Matsuo, Keitaro , McGuire, Valerie , McLaughlin, John R., McNeish, Iain A. , Menon, Usha , Moysich, Kirsten B., Ness, Roberta B., Eilber, Ursula, Odunsi, Kunle , Olson, Sara H. , Orlow, Irene , Oršulić, Sandra , Weber, Rachel Palmieri , Pearce, Celeste Leigh, Pelttari, Liisa M. , Permuth‐Wey, Jennifer, Pike, Malcolm C., Rossing, Mary Anne, Rothstein, Joseph H. , Runnebaum, Ingo B. , Rzepecka, Iwona K. , Salvesen, Helga B., Schernhammer, Eva , Schwaab, Ira, Shu, Xiao‐Ou, Shvetsov, Yurii B. , Sieh, Weiva , Song, Honglin , Southey, Melissa C. , Śpiewankiewicz, Beata, Sucheston‐Campbell, Lara, Teo, Soo‐Hwang , Terry, Kathryn L. , Thompson, Pamela J., Tangen, Ingvild L. , Tworoger, Shelley S. , Altena, Anne M. van , Vierkant, Robert A. , Vergote, Ignace , Walsh, Christine , Wang‐Gohrke, Shan , Wentzensen, Nicolas, Whittemore, Alice S. , Wicklund, Kristine G. , Wu, Anna H. , Wu, Xifeng , Woo, Yin Ling , Zheng, Wei , Kelemen, Linda E. , group, Georgia Chenevix‐Trench on behalf of the AOCS management, Schildkraut, Joellen M. , Ramus, Susan J. , Goode, Ellen L. , Monteiro, Álvaro N.A. , Gayther, Simon A. , Narod, Steven A., Sellers, Thomas A. , Phelan, Catherine M., Lu, Karen H. , Eccles, Diana , Lambrechts, Diether , Tyrer, Jonathan P. , Dennis, Joe , Anton‐Culver, Hoda , Bandera, Elisa V. , Bjørge, Line , Brooks‐Wilson, Angela , Bunker, Clareann H. , Bützow, Ralf C. , Carty, Karen , Cook, Linda S. , Cramer, Daniel W. , Cybulski, Cezary , Bois, Andreas du , Doherty, Jennifer A. , Dürst, Matthias , Eccles, Diana M., Fridley, Brooke L. , Gentry‐Maharaj, Aleksandra , Gronwald, Jacek , Hildebrandt, Michelle A.T. , Karlan, Beth Y. , Jim, Heather , Kjær, Susanne K. , Lu, Karen, McLaughlin, John R., Milne, Roger L. , Modugno, Francesmary , Nevanlinna, Heli , Paul, James , Pejovic, Tanja B. , Poole, Elizabeth M. , Risch, Harvey A. , Rosen, Barry P. , Rudolph, Anja , Siddiqui, Nadeem , Thomsen, Lotte Nedergaard , Wentzensen, Nicolas , Wilkens, Lynne R. , Yang, Hannah , Ziogas, Argyrios , Berchuck, Andrew , group, Georgia Chenevix‐Trench on behalf of the AOCS management, Pharoah, Paul D.P. , Pelttari, L M , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Kiemeney, Lambertus A , McNeish, Iain A , Ramus, Susan J , Teo, Soo H , Tworoger, Shelley S , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Lawrenson, Kate , Monteiro, Alvaro N , Moysich, Kirsten , Orlow, Irene , Lissowska, Jolanta , Campbell, Ian G , Southey, Melissa C , Glasspool, Rosalind , Lin, Hui-Yi , Matsuo, Keitaro , Heitz, Florian , Jakubowska, Anna , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Bogdanova, Natalia V , Zheng, Wei , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Genetic Epidemiology | September 24, 2015 | Volume: 39 | Issue: 8 | Pages: 689-697

10.1002/gepi.21921 | PMID 26399219 Get It

ABSTRACTEpithelial‐mesenchymal transition (EMT) is a process whereby epithelial cells assume mesenchymal characteristics to facilitate cancer metastasis. However, EMT also contributes to the initiation and development of primary tumors. Prior studies that explored the hypothesis that EMT gene variants contribute to epithelial ovarian carcinoma (EOC) risk have been based on small sample sizes and none have sought replication in an independent population. We screened 15,816 single‐nucleotide polymorphisms (SNPs) in 296 genes in a discovery phase using data from a genome‐wide association study of EOC among women of European ancestry (1,947 cases and 2,009 controls) and identified 793 variants in 278 EMT‐related genes that were nominally (P < 0.05) associated with invasive EOC. These SNPs were then genotyped in a larger study of 14,525 invasive‐cancer patients and 23,447 controls. A P‐value <0.05 and a false discovery rate (FDR) <0.2 were considered statistically significant. In the larger dataset, GPC6/GPC5 rs17702471 was associated with the endometrioid subtype among Caucasians (odds ratio (OR) = 1.16, 95% CI = 1.07–1.25, P = 0.0003, FDR = 0.19), whereas F8 rs7053448 (OR = 1.69, 95% CI = 1.27–2.24, P = 0.0003, FDR = 0.12), F8 rs7058826 (OR = 1.69, 95% CI = 1.27–2.24, P = 0.0003, FDR = 0.12), and CAPN13 rs1983383 (OR = 0.79, 95% CI = 0.69–0.90, P = 0.0005, FDR = 0.12) were associated with combined invasive EOC among Asians. In silico functional analyses revealed that GPC6/GPC5 rs17702471 coincided with DNA regulatory elements. These results suggest that EMT gene variants do not appear to play a significant role in the susceptibility to EOC.
Faculty Opinions recommendation of Differential Requirements for eIF4E Dose in Normal Development and Cancer.
Hu, Wenqian

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 24, 2015 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725579831.793509377 Get It

Axillary Ultrasound in the Management of the Newly Diagnosed Breast Cancer Patient
Al‐Hilli, Zahraa , Hieken, Tina J. , Boughey, Judy C.

Mayo Clinic

The Breast Journal | September 24, 2015 | Volume: 21 | Issue: 6 | Pages: 634-641

10.1111/tbj.12497 | PMID 26400157 Get It

A Skeptical Perspective on High-Flow Nasal Cannula in the Treatment of Acute Hypoxemic Respiratory Failure
Roberts, Christopher D. , Oeckler, Richard A.

Mayo Clinic

Respiratory Care | September 24, 2015 | Volume: 60 | Issue: 10 | Pages: 1522-1525

10.4187/respcare.04473 | PMID 26405189 Get It

Testing for Herpes Simplex Virus in Low-Volume Cerebrospinal Fluid Samples: Comparison of Three Protocols To Optimize Detection
Espy, Mark J., Irish, Cole L., Binnicker, Matthew J.

Mayo Clinic

Journal of Clinical Microbiology | September 24, 2015 | Volume: 53 | Issue: 12 | Pages: 3897-3899

10.1128/jcm.02386-15 | PMID 26400783 Get It

ABSTRACT Detection of herpes simplex virus 1 and 2 (HSV-1 and HSV-2) in cerebrospinal fluid (CSF) is a medical emergency and requires rapid, sensitive testing. However, the volume of CSF received for microbiological studies may be limited, especially from young children. In this study, we compared three testing protocols to our routine real-time PCR method to determine the most sensitive approach for detecting HSV-1 and HSV-2 in low-volume (≤100 μl) CSF.
Characterization of a Novel Integrin Binding Protein, VPS33B, Which Is Important for Platelet Activation and In Vivo Thrombosis and Hemostasis
Xiang, Binggang, Zhang, Guoying , Ye, Shaojing , Zhang, Rui , Huang, Cai , Liu, Jun , Tao, Min , Ruan, Changgeng , Smyth, Susan S. , Whiteheart, Sidney W. , Li, Zhenyu , Liu, Jun

Mayo Clinic

Circulation | September 24, 2015 | Volume: 132 | Issue: 24 | Pages: 2334-2344

10.1161/circulationaha.115.018361 | PMID 26399659 Get It

Background— Integrins are heterodimeric (α/β) membrane proteins that play fundamental roles in many biological processes, for example, cell adhesion and spreading, which are important for platelet function and hemostasis. The molecular mechanism that regulates integrin activation is not completely understood. Methods and Results— Here, we show that VPS33B, a member of the Sec1/Munc18 family, binds directly to the integrin β subunit. Overexpression of VPS33B in Chinese hamster ovary cells potentiated αIIbβ3 outside-in signaling but not inside-out signaling. Platelets, from megakaryocyte- and platelet-specific VPS33B conditional knockout mice, had normal morphology, yet their spreading on fibrinogen was impaired and they failed to support clot retraction. Platelet aggregation and ATP secretion in response to low-dose agonists were reduced in the VPS33B knockout mice. αIIbβ3-mediated endocytosis of fibrinogen was also defective. Tail bleeding times and times to occlusion in an FeCl 3 -induced thrombosis model were prolonged in the VPS33B knockout mice. Furthermore, VPS33B acted upstream of the RhoA-ROCK-MLC and Rac1-dependent pathways that lead to clot retraction and cell spreading, respectively. Conclusions— Our work demonstrates that vesicular trafficking complexes, containing VPS33B, are a novel class of modifiers of integrin function. Our data also provide insights into the molecular mechanism and treatment of arthrogryposis, renal dysfunction, and cholestasis syndrome.